Exicure director resigns; Nasdaq extends equity compliance deadline, private placement closing by Feb 21

EXICURE, INC.

Director Jeffrey Cleland resigned from board and all committees effective Feb 10, 2023.
Company non-compliant with Nasdaq independent director and audit committee requirements; cure period ongoing.
Nasdaq granted extension to file 10-K by March 31 to evidence compliance with $2.5M equity rule; risk of delisting.
Private placement of 3.4M shares at $1.60/share with CBI USA expected to close by Feb 21.

item 5.02 item 7.01 item 8.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Jeffrey L. Cleland

Director

XCUR · EXICURE, INC.

Effective: 2023-02-10
Filed: February 10, 2023, 6:59 PM ET

Effective February 10, 2023, Dr. Cleland resigned from the Board, the Audit Committee, Compensation Committee and Nominating and Corporate Governance Committee of the Board.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Jeffrey L. Cleland resigned as Director at EXICURE, INC..

Action: resigned
Role: Director

Exact text from the filing

Effective February 10, 2023, Dr. Cleland resigned from the Board, the Audit Committee, Compensation Committee and Nominating and Corporate Governance Committee of the Board.

View on SEC.gov

EXICURE, INC. filing history →

Source: SEC EDGAR

accession 0001698530-23-000010

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.